SQNM’s reported <40,000 to NATERA's 73,000 NIPT tests
DC is kicking RLs ass but the patent pool brah. Watershit moment
DC is kicking RLs ass but the patent pool brah. Watershit moment
-
Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page
RL (SQNM) vs DC (NTRA)
- Thread starter anonymous
- Start date
-
- Tags
- None
Sample numbers are not important if you are not getting pay by insurance for these samples.
OP needs to rephrase the title so that Peter Nincompoop better understands...
128mil in revenue (SQNM) vs. 190mil (NTRA)
Q4: 27.8mil (SQNM) vs 52.9 mil (NTRA)
read the transcript from the recent SQNM investor call -- our leadership DVDB and RL guided down to 120m in 2016 vs. 128m in 2015 ....hahahahahahahaha. DVDB where is that 500m in 2020 coming from? RL lies, and now you do too. # out of here
RL is a GOLDEN GOD. Don't blame the shitty performance on him. You cannot teach turds and our sales team is a bunch of turds.
RL is a GOLDEN GOD. Don't blame the failures on him. Our sales team is a bunch of turds and you can't teach turds to do anything
Two things: DC is now with Color Genomics.
Natera did slightly over 100,000 samples in Q1 with both their carrier and NIPT.
Sequenom did around 45,000 combined with both their carrier and NIPT brand.
Yikes.
Seq sits at just above $1 a share.
Natera sits at about $13.45 a share with a price target of $16 presently.
Profit up 40% quarter over quarter for Natera.
Profit down roughly 15% for Seq quarter over quarter.
Natera is getting paid for their tests now that they have in network status with all the major insurance providers.
